Equivalent Alternatives to Tresiba (Insulin Degludec)
The equivalent basal insulin alternatives to Tresiba (insulin degludec) are insulin glargine U-300 (Toujeo) and insulin glargine U-100 (Lantus/Basaglar), with unit-for-unit conversion typically appropriate when switching from degludec to other basal insulins, though a 10-20% dose reduction should be considered for patients at high hypoglycemia risk. 1
Available Basal Insulin Alternatives
The basal insulin options that can replace Tresiba include:
- Insulin glargine U-300 (Toujeo) - ultra-long-acting analog
- Insulin glargine U-100 (Lantus, Basaglar) - long-acting analog
- NPH insulin - intermediate-acting human insulin
Both longer-acting basal analogs (U-300 glargine and degludec) provide lower nocturnal hypoglycemia risk compared to U-100 glargine 1. Clinical studies demonstrate that individualized, clinically titrated doses of glargine U-300 and degludec U-100 result in equivalent glycemic control and pharmacodynamic effects 2.
Dose Conversion Guidelines
Switching FROM Tresiba TO Other Basal Insulins
Standard approach: Convert unit-for-unit initially, then adjust based on glucose monitoring 1.
For high-risk patients: Reduce the initial dose by 10-20% when:
- Patient has very tight glycemic control
- High risk for hypoglycemia exists
- Switching specifically from degludec to U-100 glargine or NPH 1
Switching TO Tresiba FROM Other Basal Insulins
Based on real-world observational data 3:
From once-daily detemir or glargine:
- Degludec dose = 3.39 + (0.78 × previous basal insulin dose)
- This typically represents approximately a 22% reduction in basal insulin dose
From twice-daily detemir or glargine:
- Degludec dose = 0.44 + (0.69 × previous total daily basal insulin dose)
- This represents approximately a 31% reduction in total basal insulin dose
Important caveat: When switching from U-100 basal insulins to ultra-long-acting insulins (degludec U-200 or glargine U-300), expect a reduction of approximately 13 units in total daily dose at 6 months 4. When replacing glargine with degludec specifically, use a lower dose to avoid hypoglycemia 5.
Clinical Considerations
Pharmacokinetic differences to remember:
- Tresiba has a half-life of approximately 25 hours and reaches steady state in 3-4 days 6
- The glucose-lowering effect lasts at least 42 hours 6
- Glargine U-300 requires slightly higher doses than degludec U-100 but provides similar 24-hour coverage 2
Monitoring after conversion:
- Intensify glucose monitoring for the first week after switching
- Allow 3-4 days for degludec to reach steady state when switching TO Tresiba 6
- Adjust doses based on fasting glucose patterns
Common pitfall: Do NOT assume insulin detemir converts unit-for-unit to other basal insulins. Detemir typically requires a 10-20% dose reduction when switching FROM it to other basal insulins 1. Similarly, U-300 glargine requires dose reduction when switching FROM it to other insulins 1.